Pre-Motor vs. Motor Cerebral Cortex Neuromodulation
For Chronic Neuropathic Pain

Igor Lavrov (igor.lavrov@gmail.com)
Mayo Clinic

Timur Latypov
University of Toronto

Elvira Mukhametova
Kazan Federal University

Brian Lundstrom
Mayo Clinic

Paola Sandroni
Mayo Clinic

Kendall Lee
Mayo Clinic

Bryan Klassen
Mayo Clinic

Matt Stead
Mayo Clinic

Research Article

Keywords: neuropathic pain, motor cortex stimulation, electrical stimulation of the cerebral cortex, neuromodulation

DOI: https://doi.org/10.21203/rs.3.rs-215297/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Electrical stimulation of the cerebral cortex (ESCC) has been used to treat intractable neuropathic pain for nearly two decades, however, no standardized approach for this technique has been developed. In order to optimize targeting and validate the effect of ESCC before placing the permanent grid, we introduced initial assessment with trial stimulation, using a temporary grid of subdural electrodes. In this retrospective study we evaluate the role of electrode location on cerebral cortex in control of neuropathic pain and the role of trial stimulation in target-optimization for ESCC. Location of the temporary grid electrodes and location of permanent electrodes were evaluated in correlation with the long-term efficacy of ESCC. The results of this study demonstrate that the long-term effect of subdural pre-motor cortex stimulation is at least the same or higher compare to effect of subdural motor or combined pre-motor and motor cortex stimulation. These results also demonstrate that the initial trial stimulation helps to optimize permanent electrode positions in relation to the optimal functional target that is critical in cases when brain shift is expected. Proposed methodology and novel results open a new direction for development of neuromodulation techniques to control chronic neuropathic pain.

Introduction

Chronic pain is clinically identified as a disabling syndrome, which is relatively frequent across the general population, affecting 8% of adults in the United States, with an incidence of about 18 million people per year. The International Association for the Study of Pain (IASP) defines chronic pain as pain experienced every day for 3 months over a period of 6 months or longer. Chronic pain can be related to variety of medical conditions and commonly leads to a complex sensory and emotional experience with variety of features. Perception of chronic pain depends on the context and meaning of the pain, the physical, psychological, and psychosocial state of the patient. The management of patients with chronic pain is considered to be one of the most difficult challenges in medicine. Various chronic pain syndromes, such as post-stroke pain, trigeminal neuralgia, or phantom limb pain are highly resistant to pharmacological treatment.

Neuromodulation techniques have been increasingly used either as a substitute for surgical treatment or in addition to pharmacological therapy. Several conditions, such as essential tremor, Parkinson's disease, dystonia, and psychiatric disorders have been successfully controlled with neuromodulation therapy. Stimulation of brain structures for the treatment of chronic pain, however, have led to variable outcomes. Several trials reported successful neuromodulation of ventral posterior lateral nucleus (VC, Ventralis Caudalis) of thalamus, periventricular grey, and periaqueductal grey deep brain stimulation (DBS) with mean relief more than 50%. Motor Cortex Stimulation (MCS) was introduced by Tsubokawa in 1991 as a treatment approach for patients with intractable pain, in response to growing frustration with inadequate DBS efficacy in this patient population. Initial studies revealed that in contrast to stimulation of the of primary sensory cortex, which increases pain, stimulation of the motor cortex causes suppression of neuropathic pain. Later MCS was found to be effective for various types of neuropathic pain (NP), such as trigeminal neuralgia, peripheral neuropathy, neuropathic pain after spinal cord injury (SCI), and others. Over the last decade MCS has emerge as a promising alternative to pharmacological therapy and for patients with drug-resistant chronic pain syndromes. Interestingly, until now, no standardized approach for MCS has been formed and there is no consensus regarding the surgical technique, electrode array implantation site, and optimal...
stimulation parameters. The surgical technique, as well as target optimization, varies between different centers with most of the institutions implanting epidural or subdural electrodes based on cortical anatomy or results of functional imaging. In order to identify cortical areas, which give the best clinical outcome with MCS, trial stimulation was introduced at Mayo Clinic and was successfully used over the last decade. In this study we retrospectively evaluated the effect of ESCC in patients treated with the inclusion of a period of trial stimulation prior to permanent implant. The electrode locations were correlated with clinical outcome. In all cases the temporary electrodes were placed in the subdural space for initial trial stimulation and, then, were replaced with permanent electrode arrays for subsequent long-term stimulation. All procedures were performed off-label based on previously reported efficacy. The outcome of motor and premotor cortex stimulation was analyzed and correlated with the position of the ‘most effective’ temporary electrode contacts and contacts on the permanent electrodes based on reconstruction of anatomical location.

Methods

Patient selection: For trial stimulation subjects initially underwent implantation of a temporary grid of electrodes (6x6 or 8x6, based on expected size of testing area of the cortex) (Fig 1A). After completing the craniotomy, the central sulcus was identified as well as the cortical region representing the primary sensory cortex. Preoperative functional MRI (fMRI) for tongue tapping and face brushing was implemented to aid in localization of these regions. Then, a temporary grid was placed in the subdural space. Data were merged with preoperative imaging in the neuronavigation workstation to guide the surgical procedure. Following placement of the chronic permanent electrode, the leads were tunneled, externalized, and connected to an external stimulus generator for trial stimulation monitoring in the intensive care unit (Fig 1B). All patients underwent postoperative CT scan to localize the position of the grid. The initial assessment with trial stimulation using a temporary grid of subdural electrodes to optimize targeting and validate the effect of stimulation before placing the permanent electrodes was started after the initial ‘honeymoon period’ had worn off (generally in about 24 hours), and when pain had increased at least to 6/10 on the VAS. The mean duration of the trial stimulation was usually 4–7 days, while patient was in the intensive care unit under continuous monitoring. Factors affecting the duration of trial stimulation included the duration of the ‘honeymoon period’, number of contacts on the temporary grid, latency to response with stimulation changes, stimulation-induced seizures, and clinical scheduling. Patients and/or nursing staff maintained an hourly pain journal to provide a guide for response to changes in stimulation parameters. Initial parameters for temporary grid trial stimulation at the motor and pre-motor cortex were: pulse width of 450 μs, rate of 40 Hz, intensity 0-4.0 V. Subjects were maintained on seizure prophylaxis with fosphenytoin throughout trial stimulation (1000 mg once during surgery and 300 mg daily during trial stimulation) and following the permanent implantation (also at 300 mg/d) for one week. Each column of the implanted subdural electrode array was tested with cathodal stimulation. If successful with the patient reporting a 50% reduction in pain (or reduction below 5/10 with baseline 8–10/10), the patient returned to the operating room for implantation of permanent electrode array for chronic stimulation (2 x 8 spinal leads, Medtronic Leads 977C265, Medtronic USA Inc) (Fig 1) connected to an internal pulse generator positioned in the (usually ipsilateral) subclavicular region. The final target for implantation of the permanent grid was adjusted based on the results of the trial stimulation. All subjects were evaluated every few weeks during the follow-up visits while chronically stimulated. All procedures were approved by the Mayo Clinic Institutional Review Board (IRB).
**Image processing for reconstruction of the electrode contact locations:** As a part of each patient's routine presurgical evaluation, a preoperative T1-weighted volumetric MRI without contrast was acquired, typically a sagittal magnetization-prepared rapid gradient echo (MPRAGE) (voxel dimensions 0.86 × 0.86 × 0.9 mm, 3T field strength), although additional coronal and axial MPRAGE and spoiled gradient recalled echo images with similar resolution were conducted as well. The preoperative MRI was converted using a DICOM to NIfTI conversion tool for Matlab and preprocessed in FreeSurfer to segment brain structures, extract the pial surface, extract the leptomeningeal surface (i.e., a smoothed pial surface), and map the patient's cortical surface to the FreeSurfer average cortical surface (Fig 2)\(^{15,16}\). As part of this process, each patient's cortical surface was mapped to the Desikan-Killiany brain atlas, which assigns each neocortical vertex to 1 of 35 areas based on gyral morphology\(^{16}\). After grid implantation, high-resolution CT images were acquired to confirm electrode placement. The post-implant CT volume was co-registered to the preoperative MRI using the FMRIB's linear image registration tool algorithm (ct2mri.sh command line tool) included in FSL via a 6 degrees of freedom affine transformation that maximized the mutual information between the 2 volumes\(^{17,18}\). Co-registered image volumes were visually inspected for accuracy. After co-registration, electrodes were manually labeled at the coregistered CT volume imported into BioImage Suite 3.0\(^{19}\). The cortical surface and electrode positions in the postimplant images were analyzed. Functional mapping (motor and sensory cortex) was not performed in this study due the absence of data on the importance of this approach in adjustment of the permanent cortical grid location. As presented earlier, the initial electrode position on CT images may shift due to loss of CSF during surgery, cerebral edema or surgical complications, such as hematoma\(^{20,21}\). To compensate for potential brain shift, subdural grid and strip electrode coordinates were projected to the leptomeningeal surface using an inverse gnomonic projection method described by Yang et al\(\text{“yangWangElecPjct (subject)”}\) in Matlab command line\(^{22}\). The surface under each grid was approximated as part of a larger sphere, and the algorithm iteratively adjusted the projection of the grid plane onto the sphere to minimize the difference between the projected and known electrode geometry. Subdural strip electrodes were assigned to the nearest leptomeningeal surface vertex. The brain shifting correction was done in MATLAB (Mathworks Inc., Natick, MA) via iELVis package\(^{23}\). iELVis was also used to identify the anatomical location of the permanent electrodes. The result of this processing is the grid location labeled at the hemisphere cortical surface mapped to the Desikan-Killiany brain atlas with defined cortex areas\(\text{“plotMgridOnPial (patient)”}\) in Matlab command line\(^{16,22}\).

**Statistical analyses:** All results are reported as means ± standard error of the mean. Statistically significant differences were determined using one-way repeated-measure ANOVA (Student-Newman-Keuls) and Student's t-test. The statistical significance level was set at p<0.05.

**Informed consent:** Informed consent, including the discussion of off-label use of FDA approved devices, was obtained from all individual participants included in the study. Following our practice of subdural cortical stimulation performed off-label, the patients underwent a two-step procedure that involved implantation of a trial electrode array followed by permanent spinal leads and an internalized pulse generator.

**Ethical statement:** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This project was limited to a
retrospective review of information from medical records within a group of patients who accepted MN research authorization. All data were analyzed anonymously with the approval of the Institutional Review Board (IRB) of our institution (ID# 18-006449) and in accordance to the usual policies and safeguards enforced by the Department of Health Science Research to protect the confidentiality of the patient record.

**Results**

Medical records of nine subjects were acquired from Mayo Clinic database from patients who underwent cortical electrode implantation procedure to treat chronic pain (Fig 1). Details on all patients selected for this study are shown in table 1. Algorithm of the image processing and post-implantation brain shift correction described in methods and outlined on Fig 2.

**Trial stimulation:** Retrospective review of programming records demonstrated that after surgical implantation of the permanent grid, all subjects in this study (n= 9) reported a "honeymoon effect" with significant improvement in pain during the first one to two days after surgery without active stimulation. Because of 'honeymoon effect', trial stimulation was delayed until the pain level exceeded 5/10 on the VAS. Parameters of stimulation (frequency, pulse width, and stimulation intensity) were adjusted individually during trail stimulation and permanent stimulation and varied depending on pain reduction and side-effects. Initial settings were: 40Hz, 450 µsec, 0-4 V. In two cases, stimulation frequency was increased up to 100Hz (subjects 4 and 9), when the initial settings did not improve pain. Trial stimulation was started on day 1 (n=3), 2 (n=1), 3 (n=3), or day 4 (n=1) after temporary grid placement. In all subjects except one, the initial trial stimulation reduced the pain intensity in more than 50%, although one subject (subject 9) showed less reduction in pain and after trial stimulation his pain level was 5/10, comparing with 9-10/10 at baseline before implantation. The mean pain level by the end of the trial stimulation was 1.92±0.4 (n=9). Based on results of trial stimulation the areas of stimulation with the most effective pain control were identified as a target for permanent grid placement (Fig 1). Trial stimulation was also helpful in evaluation of potential side effects of ESCC, i.e. problems with speech, muscles spasm or twitches, focal seizures, and in some cases increased pain (Table 2). For all cases, the final target for implantation of permanent grid was adjusted based on results of the trial stimulation.

**Chronic stimulation:** All subjects then underwent implantation of the permanent electrodes (2 x 8 spinal leads) centered over the most effective leads of the initial trial stimulation, except subject 9, who developed postoperative hematoma. After recovery from the 2nd surgery, they were evaluated and discharged with follow-up visits and evaluations based on regular reports. Based on results of retrospective analysis, patients with electrodes implanted over motor or motor and premotor areas (n=6), yielded at least 70% pain reduction on the average and stated stable pain relief up to 0-4 / 10 on the VAS (Fig 3). Patients with permanent electrodes placed over the premotor area (n=2) yielded significant pain reduction and stated pain relief up to 0-1 on pain scale that was significantly better compare to other patients (Fig 3 and Fig 4). We identified one patient (Subject 9) with permanent electrodes covering the motor, pre-motor cortex, and also sensory cortex, who did not demonstrate significant pain relief (~5%). This patient had a postsurgical hematoma and permanent grid was implanted after hematoma evacuation without trial stimulation. Six months to one-year follow-up after permanent electrodes implantation in this subject demonstrated that stimulation with
permanent electrodes implanted over motor, premotor, and sensory areas, pain gradually increased up to the preoperative level (Fig 4). In six subjects with electrodes located over premotor and motor area, pain reduction slightly decreased by 15%. However, two subjects with electrodes placed on premotor area did not show significant fluctuation in pain level over time (Table 2). At six-month follow up visit, all subjects who had a significant pain relief during trial stimulation demonstrated stable pain control (Fig 4). In contrast, subjects, who had improvement less than 50% from the pre-operative level, demonstrated some level of decline in effect of ESCC to control chronic pain (Table 2). The analysis of the effect of ESCC to alleviate chronic pain in correlation with the location of permanent electrodes suggests that the neuromodulation of premotor cortical area may be as beneficial as, or better than primary motor cortex stimulation. The reconstruction of permanent electrodes location on average brain model demonstrated that subjects with significant pain relief have electrodes primarily on pre-motor cortex (Fig 5).

**Discussion**

The surgical treatment of neuropathic pain with ESCC has been evolving over last decades, starting from the first implantation, reported by Tsubokawa and colleagues \(^8\). Most of the centres currently using image guidance with MRI to localize the region of the pain, i.e. in case of facial pain – anterior to the central sulcus at the level of the inferior frontal sulcus \(^8\). This information then loaded into a neuronavigation workstation to direct the most appropriate location for the incision and craniotomy. Typically, the specific region of motor cortex is identified through intraoperative somato-sensory evoked potentials (SSEP) and confirmed by trial intraoperative stimulation \(^8,10\). In addition, TMS can be useful for non-invasive trial stimulation and might potentially be considered as an assessment tool for cortical stimulation efficiency \(^24\). The surgical technique, however, varies significantly between institutions, with most centers placing electrodes in the epidural space. Epidural placement has several advantages including lower operative risk and shorter operative time, however, epidural electrode placement often leads to a scarring around the electrodes, resulting in higher electrode impedance and consequent declines in stimulation efficacy over time \(^25,26\). Epidural stimulation can also lead to less localized stimulation and may require a higher stimulus intensity, which usually results in shorter battery life. Epidural stimulation may also induce pain by direct activation of the dural pain fibers, limiting therapeutic effect of stimulation \(^4,14,27\). In a computer simulation study, Kim et al. compared the efficacy of both epidural and subdural placement and reported that the effective volume and depth of pulse penetration is significantly higher with subdural stimulation compared to epidural \(^28,29\). Placing stimulating electrodes in the subdural space routinely over last ten years we have shown consistent results with minimal surgical complication \(^14,30\).

Regardless of the long history of ESCC, the mechanisms responsible for alleviating of chronic pain are largely unknown. In animal studies it has been demonstrated that after deafferentation of reticular thalamic nucleus and ventral posterior lateral thalamus, normal thalamocortical circuitry activity shifts from high-threshold tonic firing to low-threshold theta-range oscillatory bursts \(^31\). This transformation further leads to a decrease in the excitatory input to the reticular thalamus and their subsequent hyperpolarization and low-frequency bursting that induces rhythmic discoordination of the thalamocortical loops in theta frequency band \(^32\). Based on these observations it was proposed that cortical stimulation may inhibit the hyperactivity of the thalamus
and particularly the sensory nuclei of the thalamus that exhibit chronic pain-induced hyperactivity with increased spike density. In fact, outcomes of multiple trials suggest that the mechanisms of neuropathic pain that respond to the cortical stimulation may have a final common pathway of deafferentation at the different levels of the sensory system. Later, it was shown that cortical stimulation may initially activate the axons that run horizontally in the precentral gyrus, parallel to the surface of the cortex. These cortico-cortical projections directed from primary motor to primary sensory cortex, and travel in Layer I, making them easily accessible for stimulation. These results altogether support the commonly accepted hypothesis that during neuropathic pain, most of the cortical inputs tend to balance pathological thalamocortical oscillations and may also facilitate following reorganization in these areas, while cortical stimulation targeting the same mechanisms could further compensate pathological oscillations and related neuropathic pain. The brain areas with relatively higher degree of functional connectivity and plasticity, like premotor and motor cortical areas, could be particularly effective in compensation of central deafferentation. Multiple studies suggest that cortical stimulation can lead to reinforcement of intracortical GABAergic inhibition, increased secretion of endogenous opioids in various structures and more specifically, the cingulate cortex and periaqueductal gray matter (PAG). It was also found that the density of opioid receptors binding in the brain is correlated with postoperative pain relief with cortical stimulation in patients with chronic pain. Another mechanism of ESCC could be related with activation of cortical and mesencephalic areas involved in the emotional appraisal of pain, particularly insula, cingulate, and orbitofrontal cortex.

Only few studies have explored the effect of cortical stimulation on various pain syndromes (Supplementary table 1) with total of over few hundreds participants evaluated. Most of reports with MCS are focusing on trigeminal neuralgia and post stroke pain treatment. Trigeminal neuralgia generally showed a good response to cortical stimulation with more than a half of the patients receiving significant pain relief. Several recent reviews indicate that 75-85% of patients have at least 50% reduction of trigeminal pain with motor cortex stimulation. Results however, vary between the centers. In contrast with trigeminal neuralgia, there is a lack of clinical trials on cortical stimulation for phantom limb pain with only few case-reports and mixed trials with small number of patients. Recently we reported an improvement of phantom limb syndrome with cortical stimulation in two subjects along with other studies demonstrating effect of cortical stimulation on phantom limb pain. Currently, the implantable neuromodulation systems for MCS in patients with chronic pain are considered "off label" which significantly limits further exploration of this technique. MCS can lead to several complications, typical for most craniotomies, such as infection and hemorrhage (Supplementary table 1). In several trials cortical stimulation has been associated with focal seizures during stimulation, although, it disappeared when stimulation was stopped. The seizure threshold does appear to respond to standard anticonvulsants (e.g. levetiracetam or fosphenytoin) that were used in this study. Henderson et al. reported that seizures were associated primarily with stimulus rates between 70 and 90Hz and patients who experience seizures did not develop chronic epilepsy. In this retrospective study we report several surgical complications, which did not affect the outcome, except one subject with hematoma, which led to the brain shift and electrode misplacement.

Summarizing these results, we can outline two key outcomes of this study. The first outcome indicates on specific role of electrode location in the efficacy of cortical stimulation to control chronic neuropathic pain,
and particularly the effect of pre-motor cortex stimulation. Most of the previous studies were focused on neuromodulation of the motor cortex, after initially negative experience with S1 stimulation. The effect of premotor cortex stimulation was not studied and remained largely unknown. In contrast to a somatotopic organization (motor homunculus), premotor cortex is likely organized in a functional manner, where overlapped regions represent different motor patterns. This organization has been supported by several studies in animals, and indicates that the areas of cerebral cortex controlling specific part of the body in premotor cortex may have more diffuse and overlapped representations compared to M1, i.e. related to complex sensorimotor functions with involvement of multiple body parts and may have higher cortical plasticity. This specific organization was primarily suggested by animal studies and still needs to be confirmed in humans. Recent works suggest that premotor cortex along with primary motor cortex, primary sensory cortex, and prefrontal cortex are organized in a neuronal network responsible for complex control of movements and sensorimotor integration (Fig 6). Specific mechanisms of this organization and functioning of this network still need to be investigated and may further facilitate development of new strategies for treatment of neuropathic pain.

The first outcome of this study indicates on importance of trial stimulation for target optimization. According to these results, initial reduction in pain, observed during trial stimulation, was consistent during chronic stimulation for most of the tested subjects. Those who did not respond to trial stimulation, in fact, did not improve, even after multiple adjustments. These findings suggest that trial stimulation provides important information for positioning of permanent electrodes and helps to assess individual response to initial stimulation settings. Trial stimulation started after the 'honeymoon period', when the pain is returning to the baseline, can help to avoid misinterpretation of results of trial stimulation. The main disadvantage of trial stimulation with temporary grids is surgical side effects, i.e. increased risk of hematoma and loss of CSF. In combination, this leads to the shifting from initially planned position and may result in displacement of the permanent grid that we observed in one subject. To our knowledge this is the first study with cortical stimulation for neuropathic pain that describes the effect of trial stimulation. Retrospective analysis of DBS implantations has been performed previously for evaluation of the electrode shift and did not find significant displacement with postoperative intracranial air volume up to 35 cm³, although, DBS electrodes are less affected by the brain shift due to their deeper locations.

In conclusion, the results of this study suggest that modulation of neural networks with subdural ESCC is beneficial and provides control of neuropathic pain when located on motor and particularly on pre-motor areas. The most important and novel finding of this study is that pre-motor cortex stimulation is at least as beneficial as motor cortex stimulation and can be considered for future therapy with ESCC. In cases of complex pain syndromes, i.e. thalamic pain, regional pain syndrome, or spinal cord injury-associated pain, premotor cortex stimulation could provide additional benefits through the coverage the wider functional area. Another important finding of this study is that trial stimulation for target optimization can significantly improve the outcome of ESCC. Future differentiation of specific mechanisms related to effect of ESCC could improve pain control in cases when access to the motor cortex is limited or the effect of stimulation is insufficient.

Declarations
Acknowledgement

No financial and personal relationships with other people or organizations.

Competing interests
The authors declare no competing interests

Financial interests
The authors declare no financial interests

Funding: N/A

Data sharing
Data collected for the study were deidentified and will be available with publication.

Author contributions statements

IL and MS conceived the study and were the coordinating investigators. IL, BK, KL and MS designed the study protocol. TL, IL, and BK oversaw image quality assurance, and analyzed all available images and did the statistical analysis. IL and TL wrote the first draft of the article. IL, TL, EM, BL, PS, MS, and BK built a writing committee to work on the further drafts of the Article, which was reviewed by all authors. All authors contributed to data acquisition, management, and brain imaging analyses. All authors contributed to critical revision of the manuscript and approved the final manuscript for submission.

References

1. Jensen, M. P., Chodroff, M. J. & Dworkin, R. H. The impact of neuropathic pain on health-related quality of life: Review and implications. Neurology vol. 68 1178–1182 (2007).
2. MERSKEY & N. Classificaion of chronic pain; Description of chronic pain syndromes and deinitions of pain Terms. Task force Taxon. Int. Assoc. study pain 41–43 (1994).
3. Bushnell, M. C., Čeko, M. & Low, L. A. Cognitive and emotional control of pain and its disruption in chronic pain. Nature Reviews Neuroscience vol. 14 502–511 (2013).
4. Delavallée, M., Abu-Serieh, B., De Tourchaninoff, M. & Raftopoulos, C. Subdural motor cortex stimulation for central and peripheral neuropathic pain: A long-term follow-up study in a series of eight patients. Neurosurgery 63, 101–105 (2008).
5. Cruccu, G. et al. EFNS guidelines on neurostimulation therapy for neuropathic pain. Eur. J. Neurol. 14, 952–970 (2007).
6. Kumar, K., Toth, C. & Nath, R. K. Deep Brain Stimulation for Intractable Pain: A 15-Year Experience. Neurosurgery 40, 736–747 (1997).
7. Hamani, C. et al. Deep brain stimulation for chronic neuropathic pain: Long-term outcome and the incidence of insertional effect. Pain 125, 188–196 (2006).
8. TSUBOKAWA, T., KATAYAMA, Y., YAMAMOTO, T., HIRAYAMA, T. & KOYAMA, S. Treatment of Thalamic Pain by Chronic Motor Cortex Stimulation. *Pacing Clin. Electrophysiol.* **14**, 131–134 (1991).

9. Levy, R., Deer, T. R. & Henderson, J. Intracranial neurostimulation for pain control: A review. *Pain Physician* vol. 13 157–165 (2010).

10. Nguyen, J. P. *et al.* Motor cortex stimulation in the treatment of central and neuropathic pain. *Arch. Med. Res.* **31**, 263–265 (2000).

11. Fontaine, D., Hamani, C. & Lozano, A. Efficacy and safety of motor cortex stimulation for chronic neuropathic pain: Critical review of the literature - Clinical article. *J. Neurosurg.* **110**, 251–256 (2009).

12. Fiocchi, S., Chiaramello, E., Ravazzani, P. & Parazzini, M. Modelling of the Current Density Distributions during Cortical Electric Stimulation for Neuropathic Pain Treatment. *Comput. Math. Methods Med.* **2018**, (2018).

13. Honey, C. M., Tronnier, V. M. & Honey, C. R. Deep brain stimulation versus motor cortex stimulation for neuropathic pain: A minireview of the literature and proposal for future research. *Comput. Struct. Biotechnol. J.* **14**, 234–237 (2016).

14. Thomas, L., Bledsoe, J. M., Sandroni, P., Gorman, D. & Lee, K. H. Motor cortex and deep brain stimulation for the treatment of intractable neuropathic face pain. *Curr. Neurol. Neurosci. Rep.* **9**, 120–126 (2009).

15. Dale, A. M., Fischl, B. & Sereno, M. I. Cortical surface-based analysis: I. Segmentation and surface reconstruction. *Neuroimage* **9**, 179–194 (1999).

16. Desikan, R. S. *et al.* An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. *Neuroimage* **31**, 968–980 (2006).

17. Jenkinson, M. & Smith, S. A global optimisation method for robust affine registration of brain images. *Med. Image Anal.* **5**, 143–156 (2001).

18. Jenkinson, M., Bannister, P., Brady, M. & Smith, S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. *Neuroimage* **17**, 825–841 (2002).

19. Joshi, A. *et al.* Unified framework for development, deployment and robust testing of neuroimaging algorithms. *Neuroinformatics* **9**, 69–84 (2011).

20. Hastedr, P. *et al.* Strategies for brain shift evaluation. *Med. Image Anal.* **8**, 447–464 (2004).

21. Hill, D. L. G. *et al.* Sources of error in comparing functional magnetic resonance imaging and invasive electrophysiological recordings. *J. Neurosurg.* **93**, 214–223 (2000).

22. Yang, A. I. *et al.* Localization of dense intracranial electrode arrays using magnetic resonance imaging. *Neuroimage* **63**, 157–165 (2012).

23. Groppe, D. *et al.* iELVis: An open source MATLAB toolbox for localizing and visualizing human intracranial electrode data. *iELVis An open source MATLAB toolbox localizing Vis. Hum. intracranial electrode data* 069179 (2016) doi:10.1101/069179.

24. André-Obadia, N. *et al.* Transcranial magnetic stimulation for pain control. Double-blind study of different frequencies against placebo, and correlation with motor cortex stimulation efficacy. *Clin. Neurophysiol.* **117**, 1536–1544 (2006).

25. Saitoh, Y. *et al.* Motor cortex stimulation for central and peripheral deafferentation pain. *J. Neurosurg.* **92**, 150–155 (2000).
26. Velasco, F. et al. Motor cortex electrical stimulation applied to patients with complex regional pain syndrome. *Pain* **147**, 91–98 (2009).

27. Tronnier, V. & Rasche, D. Epidural and subdural stimulation. *Handb. Clin. Neurol.* **116**, 343–351 (2013).

28. Kim, D., Jun, S. C. & Kim, H. I. Computational study of subdural and epidural cortical stimulation of the motor cortex. *Proc. Annu. Int. Conf. IEEE Eng. Med. Biol. Soc. EMBS* **7226–7229** (2011) doi:10.1109/IEMBS.2011.6091826.

29. Monsalve, G. A. Motor cortex stimulation for facial chronic neuropathic pain: A review of the literature. *Surg. Neurol. Int.* **3**, (2012).

30. Krushelnytskyy, M. D. et al. Chronic subdural cortical stimulation for phantom limb pain: report of a series of two cases. *Acta Neurochir. (Wien)*. **161**, 925–934 (2019).

31. Steriade, M., Domich, L., Oakson, G. & Deschenes, M. The deafferented reticular thalamic nucleus generates spindle rhythmicity. *J. Neurophysiol.* **57**, 260–273 (1987).

32. Steriade, M. Central core modulation of spontaneous oscillations and sensory transmission in thalamocortical systems. *Curr. Opin. Neurobiol.* **3**, 619–625 (1993).

33. Lefaucheur, J. P. et al. Motor cortex stimulation for the treatment of refractory peripheral neuropathic pain. *Brain* **132**, 1463–1471 (2009).

34. Maarrawi, J. et al. Motor cortex stimulation for pain control induces changes in the endogenous opioid system. *Neurology* **69**, 827–834 (2007).

35. García-Larrea, L. et al. Electrical stimulation of motor cortex for pain control: A combined PET-scan and electrophysiological study. *Pain* **83**, 259–273 (1999).

36. García-Larrea, L. & Peyron, R. Motor cortex stimulation for neuropathic pain: From phenomenology to mechanisms. *Neuroimage* **37**, (2007).

37. Ebel, H., Rust, D., Tronnier, V., Böker, D. & Kunze, S. Chronic precentral stimulation in trigeminal neuropathic pain. *Acta Neurochir. (Wien)*. **138**, 1300–1306 (1996).

38. Parmar, V. K., Gee, L., Smith, H. & Pilitsis, J. G. Supraspinal stimulation for treatment of refractory pain. *Clin. Neurol. Neurosurg.* **123**, 155–163 (2014).

39. Roux, F. E., Ibarrola, D., Lazorthes, Y. & Berry, I. Chronic motor cortex stimulation for phantom limb pain: A functional magnetic resonance imaging study: Technical case. *Neurosurgery* **48**, 681–688 (2001).

40. Pereira, E. A. C., Moore, T., Moir, L. & Aziz, T. Z. Long-term motor cortex stimulation for phantom limb pain. *Br. J. Neurosurg.* **29**, 272–274 (2015).

41. Raslan, A. M., Nasseri, M., Bahgat, D., Abdu, E. & Burchiel, K. J. Motor cortex stimulation for trigeminal neuropathic or deafferentation pain: An institutional case series experience. *Stereotact. Funct. Neurosurg.* **89**, 83–88 (2011).

42. Machado, A. G., Mogilner, A. Y. & Rezai, A. R. Motor Cortex Stimulation for Persistent Non-cancer Pain. in *Textbook of Stereotactic and Functional Neurosurgery* 2239–2249 (Springer Berlin Heidelberg, 2009). doi:10.1007/978-3-540-69960-6_132.

43. Meyerson, B. A., Lindblom, U., Linderoth, B., Lind, G. & Herregodts, P. Motor cortex stimulation as treatment of trigeminal neuropathic pain. *Acta Neurochir. Suppl. (Wien)*. **58**, 150–153 (1993).
44. The Cerebral Cortex of Man: A Clinical Study of Localization of Function. *J. Am. Med. Assoc.* **144**, 1412 (1950).

45. Aflalo, T. N. & Graziano, M. S. A. Possible origins of the complex topographic organization of motor cortex: reduction of a multidimensional space onto a two-dimensional array. *J. Neurosci.* **26**, 6288–6297 (2006).

46. Graziano, M. S. A. Ethological Action Maps: A Paradigm Shift for the Motor Cortex. *Trends Cogn. Sci.* **20**, 121–132 (2016).

47. Buccino, G. *et al.* Action observation activates premotor and parietal areas in a somatotopic manner: An FMRI study. in *Social Neuroscience: Key Readings* vol. 9780203496190 133–142 (Taylor and Francis, 2013).

48. Abe, M. & Hanakawa, T. Functional coupling underlying motor and cognitive functions of the dorsal premotor cortex. *Behav. Brain Res.* **198**, 13–23 (2009).

49. Graziano, M. S. A. & Aflalo, T. N. Mapping behavioral repertoire onto the cortex. *Neuron* **56**, 239–251 (2007).

50. Hanakawa, T. Rostral premotor cortex as a gateway between motor and cognitive networks. *Neurosci. Res.* **70**, 144–154 (2011).

51. Slotty, P. J. *et al.* The impact of brain shift in deep brain stimulation surgery: Observation and obviation. *Acta Neurochir. (Wien).* **154**, 2063–2068 (2012).

52. Carroll, D. *et al.* Motor cortex stimulation for chronic neuropathic pain: A preliminary study of 10 cases. *Pain* **84**, 431–437 (2000).

53. Rasche, D., Ruppolt, M., Stippich, C., Unterberg, A. & Tronnier, V. M. Motor cortex stimulation for long-term relief of chronic neuropathic pain: A 10 year experience. *Pain* **121**, 43–52 (2006).

54. Velasco, F. *et al.* Efficacy of motor cortex stimulation in the treatment of neuropathic pain: A randomized double-blind trial. *J. Neurosurg.* **108**, 698–706 (2008).

**Tables**

**Table 1.** Summary of initial clinical findings for patients in this study.
| Subject number | Age | Sex | Main Diagnosis | Coexisting diagnosis | Pain duration (years) | Medications |
|----------------|-----|-----|----------------|----------------------|-----------------------|-------------|
| 1              | 66  | m   | Central post-stroke syndrome affecting left arm and leg | Stroke, hyperlipidemia, history of depression and anxiety, obesity, orthostatic hypotension, impaired fasting glucose | 15 | Clonazepam, dronabinol, gabapentin, venlafaxine |
| 2              | 45  | m   | Phantom limb pain (left upper extremity) | | 5 | Amitriptyline, gabapentin, DREZsurgery |
| 3              | 83  | m   | Phantom pain (left upper extremity) | | 58 | Gabapentin, duloxetine, amitriptyline |
| 4              | 61  | m   | Left facial pain with a anesthesia dolorosa and SUNCT | DM type 2, hypertension | 21 | Indomethacin, venlafaxine |
| 5              | 61  | f   | Right upper facial pain | | 3.5 | Hydrocodone, baclofen, gabapentin |
| 6              | 40  | f   | Right trigeminal neuralgia V2,3 | History of non-psychotic major depression and anxiety, PTSD | 1.8 | Acetaminophen, lorazepam, oxcarbazepine, promethazine |
| 7              | 55  | f   | Left trigeminal neuralgia and subsequent anesthesia dolorosa | Anxiety secondary | 3.3 | Anastrozole, baclofen, diazepam |
| 8              | 61  | f   | Right trigeminal neuralgia | | 13.5 | Hydrocodone, cyclobenzaprine, lamotrigine, topiramate |
| 9              | 59  | f   | Chronic left greater right lower face and left parietal scalp pain | Laminectomy and L4-5 fusion | 2.5 | Oxycodone, gabapentin, lidocaine, diclofenac, methadone |

DM- diabetes mellitus; PTSD- posttraumatic stress disorder. DREZ- dorsal root entry zone.

Table 2. Results of trial stimulation with temporary and permanent grid.
| Subject number | Pain type | PO-pain (VAS) | Trial stimulation | Permanent stimulation | Side effects | Permanent electrode placement |
|----------------|-----------|---------------|-------------------|-----------------------|--------------|-------------------------------|
|                |           |               | Start             | End                   |              |                               |
|                |           |               | Day VAS Day VAS   | 7-14 days (VAS) 6-12 m follow-up* |              |                               |
| 1              | CPSleft   | 9-10          | 3 5 8 2 2 2       | Focal seizure, intermittent dysarthria (T) | Motor Premotor |
| 2              | PhPleft   | 8-10          | 1 4-5 5 2 2 2-3   | Epidural, subdural hematoma (T) | Motor Premotor |
| 3              | PhPleft   | 5-10          | 1 5 7 0-1 0-1 1   | Headache | Motor Premotor |
| 4              | RFP       | 8-9           | 3 8 8 3 3 5       | Intermittent Broca's aphasia, incisional pain (T\P) | Motor Premotor |
| 5              | LFP       | 8-9           | 1 5 3 3-4 3-4 4-5 | Intermittent facial twitching (T) | Motor Premotor |
| 6              | RFP       | 9-10          | 4 6-7 6 0 0 5     | Intermittent right side seizures, Broca's aphasia(T) | Motor Premotor |
| 7              | LFP       | 6-10          | 2 7 7 0 0 0       | Throat spasm, whole body shaking w/o loss of conscious (T) | Premotor |
| 8              | RFP       | 9-10          | 3 7 8 0-1 0-1 0-1 | Intermittent Broca's aphasia(T) | Premotor |
| 9              | LFP       | 9-10          | 0 5 0 8 8 8-10    | Subdural hematoma (T) | Sensory Motor Premotor |
PO pain-preoperative pain level; Trial stimulation - mapping with temporary grid stimulation: start day - days after temporary grid implantation; start VAS - pain by the trial stimulation beginning; end day - trial stimulation end after temporary grid implantation; end VAS - pain by the end of trial stimulation; Chronic stimulation - stimulation with permanent grid: VAS score within 6-12 months of observation is considered as an average pain level during this period that achieved after stimulation parameters adjustment and adequate battery charge. CPS left - central poststroke pain syndrome with left-side clinical presentation; PhP left – left side phantom pain, RFP – right fascial pain; LFP – left fascial pain.